Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

This study is testing whether acalabrutinib — a targeted drug used for blood cancers — given as maintenance therapy after stem cell transplant or CAR-T cell therapy can prevent large B-cell lymphoma from returning. Patients in this high-risk group often relapse after these intensive treatments, and researchers hope this approach can extend remission. **You may be eligible if...** - You are between 18 and 70 years old - You have large B-cell lymphoma and have undergone a stem cell transplant (autologous or allogeneic) or an FDA-approved CAR-T cell therapy - Your lymphoma falls into a high-risk category (e.g., double/triple hit lymphoma, CNS involvement, high IPI score, or transformed from another lymphoma) - You achieved at least a partial response before transplant or after CAR-T - You are in good enough physical condition (ECOG 0-2) **You may NOT be eligible if...** - You are older than 70 - Your response to transplant or CAR-T therapy was insufficient (less than partial response) - You have active infections or serious organ problems - You are enrolled too late after transplant (beyond day 90 for transplant, or day 104 for CAR-T) Talk to your doctor to see if this trial is right for you.